Compare Amylx Pharmaceuticals Inc (AMLX) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.65 (market cap $1.98B), while Vanguard Ultra Short Bond ETF trades at $49.65. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | VUSB | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $18.70 | $50.03 |
52-Week Low | $7.64 | $49.60 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
VUSB trades at $49.66 with minimal daily movement, showing a slight 0.01% gain. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators are neutral. The ETF offers a yield of approximately 4.35% and is positioned as a cash alternative amid a non-inverted yield curve, with recent dividends paid in mid-2026.
The outlook for VUSB is cautious due to bearish technicals and potential Fed rate increases in 2026, which could impact short-term bonds. Risks include interest rate sensitivity and credit/duration exposure, but the ETF remains a viable option for investors seeking yield above money-market funds with moderate risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
